Amitriptylinoxide: receptor-binding profile compared with other antidepressant drugs

Area of Science:

• Pharmacology
• Neuroscience
• Medicinal Chemistry

Background:

• Tricyclic antidepressants (TCAs) like amitriptyline are widely used but associated with significant side effects.
• Understanding the receptor interaction profiles of TCA metabolites and analogs is crucial for developing safer and more effective treatments.
• Amitriptylinoxide, a metabolite of amitriptyline, warrants investigation for its distinct pharmacological properties.

Purpose of the Study:

• To investigate the receptor binding interactions of amitriptylinoxide compared to amitriptyline and other antidepressants.
• To determine the affinity of amitriptylinoxide for various neurotransmitter and drug receptors.
• To correlate receptor binding profiles with potential clinical effects, including side effects and efficacy.

Main Methods:

• Receptor binding assays were employed to quantify the affinity of amitriptylinoxide and other antidepressants.
• Specific receptor targets included acetylcholine, alpha-adrenergic, benzodiazepine, opiate, and beta-adrenergic receptors.
• Half maximal inhibitory concentration (IC50) values were determined for ligand displacement.

Main Results:

• Amitriptylinoxide demonstrated significantly lower binding affinity for most studied receptors compared to amitriptyline.
• Specifically, amitriptylinoxide showed a much weaker affinity for acetylcholine receptors (18 µmol/L vs. 0.32 µmol/L for amitriptyline).
• Amitriptylinoxide exhibited the weakest affinity among tested tricyclic compounds for muscarinic acetylcholine receptors and a 60-fold lower affinity for alpha-receptors than amitriptyline.

Conclusions:

• The reduced receptor binding affinity of amitriptylinoxide likely contributes to its milder side effect profile.
• Despite weaker receptor interactions, amitriptylinoxide may retain antidepressant properties by influencing brain amitriptyline levels.
• These findings suggest amitriptylinoxide as a potential therapeutic agent with an improved safety profile compared to traditional TCAs.